Anti-programmed cell death 1/programmed cell death ligand 1(PD-1/PD-L1) inhibitors were recommended in clinical guidelines as first and second-line treatments for select patients with advanced bladder cancer [1]. Here, CD274 is linked to urinary bladder carcinoma.